nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

05.10.2016 | Review – Clinical Oncology

β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives

verfasst von: Marisa Coelho, Cátia Soares-Silva, Daniela Brandão, Franca Marino, Marco Cosentino, Laura Ribeiro

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In this review, we aimed to present and discuss the available preclinical and epidemiological evidences regarding the modulation of cancer cell proliferation by β-adrenoceptors (β-AR), with a specific focus on the putative effects of β-blockers according to their pharmacological properties.

Methods

A comprehensive review of the published literature was conducted, and the evidences concerning the involvement of β-AR in cancer as well as the possible role of β-blockers were selected and discussed.

Results

The majority of reviewed studies show that: (1) All the cancer types express both β1- and β2-AR, with the exception of neuroblastoma only seeming to express β2-AR; (2) adrenergic agonists are able to increase proliferation of several types of cancers; (3) the proliferative effect seems to be mediated by both β1- and β2-AR; (4) binding to β-AR results in a cAMP transient flux which activates two major downstream effector systems: protein kinase A and EPAC and (5) β-blockers might be putative adjuvants for cancer treatment.

Conclusions

Overall, the reviewed studies show strong evidences that β-AR activation, through several intracellular mechanisms, modulate tumor cell proliferation suggesting β-blockers can be a feasible therapeutic approach to antagonize β-adrenergic response or have a protective effect per se. This review highlight the need for intensifying the research not only on the molecular mechanisms underlying the β-adrenergic influence in cancer, but also on the implications of biased agonism of β-blockers as potential antitumor agents.

Al-Wadei HA, Al-Wadei MH, Schuller HM (2012a) Cooperative regulation of non-small cell lung carcinoma by nicotinic and β-adrenergic receptors: a novel target for intervention PloS One 7:e29915. doi:10.1371/journal.pone.0029915 PubMed

Al-Wadei HA, Ullah MF, Al-Wadei MH (2012b) Intercepting neoplastic progression in lung malignancies via the β adrenergic (β-AR) pathway: implications for anti-cancer drug targets. Pharmacol Res 66:33–40. doi:10.1016/j.phrs.2012.03.014 CrossRefPubMed

Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK (2009) Neuroendocrine modulation of cancer progression. Brain Behav Immun 23:10–15. doi:10.1016/j.bbi.2008.06.007 CrossRefPubMed

Armaiz-Pena GN et al (2015) Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget 6:4266–4273. doi:10.18632/oncotarget.2887 CrossRefPubMed

Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Pineyro G (2003) Β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406–11411. doi:10.1073/pnas.1936664100 CrossRefPubMedPubMedCentral

Baker JG, Hall IP, Hill SJ (2003) Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses. Mol Pharmacol 64:679–688. doi:10.1124/mol.64.3.679 CrossRefPubMed

Baker JG, Hill SJ, Summers RJ (2011) Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci 32:227–234. doi:10.1016/j.tips.2011.02.010 CrossRefPubMedPubMedCentral

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Β blockers and breast cancer mortality: a population- based study. J Clin Oncol 29:2635–2644. doi:10.1200/jco.2010.33.5422 CrossRefPubMed

Bernabé DG, Tamae AC, Biasoli ER, Oliveira SH (2011) Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. Brain Behav Immun 25:574–583CrossRefPubMed

Bravo-Calderon DM, Oliveira DT, Marana AN, Nonogaki S, Carvalho AL, Kowalski LP (2011) Prognostic significance of β-2 adrenergic receptor in oral squamous cell carcinoma. Cancer Biomark 10:51–59. doi:10.3233/cbm-2012-0228 CrossRefPubMed

Cakir Y, Plummer HK 3rd, Tithof PK, Schuller HM (2002) Β-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol 21:153–157PubMed

Calvani M et al (2015) Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progression. Oncotarget 6:4615–4632. doi:10.18632/oncotarget.2652 CrossRefPubMed

Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S (2009) Catecholamines regulate tumor angiogenesis. Cancer Res 69:3727–3730. doi:10.1158/0008-5472.can-08-4289 CrossRefPubMed

Chida Y, Hamer M, Wardle J, Steptoe A (2008) Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 5:466–475. doi:10.1038/ncponc1134 CrossRefPubMed

Childers WK, Hollenbeak CS, Cheriyath P (2015) β-Blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clin Breast Cancer 15:426–431. doi:10.1016/j.clbc.2015.07.001 CrossRefPubMed

Choi CH et al (2014) Meta-analysis of the effects of β blocker on survival time in cancer patients. J Cancer Res Clin Oncol 140:1179–1188. doi:10.1007/s00432-014-1658-7 CrossRefPubMed

Coelho M, Moz M, Correia G, Teixeira A, Medeiros R, Ribeiro L (2015) Antiproliferative effects of β-blockers on human colorectal cancer cells. Oncol Rep 33:2513–2520. doi:10.3892/or.2015.3874 PubMed

Cole SW, Sood AK (2012) Molecular pathways: β-adrenergic signaling in cancer. Cancer Res 18:1201–1206. doi:10.1158/1078-0432.ccr-11-0641

Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK (2015) Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer 15:563–572. doi:10.1038/nrc3978 CrossRefPubMedPubMedCentral

Colucci R, Moretti S (2016) The role of stress and β-adrenergic system in melanoma: current knowledge and possible therapeutic options. J Cancer Res Clin Oncol 142:1021–1029. doi:10.1007/s00432-015-2078-z CrossRefPubMed

Cosentino M et al (2000) HPLC-ED measurement of endogenous catecholamines in human immune cells and hematopoietic cell lines. Life Sci 68:283–295CrossRefPubMed

Cosentino M, Marino F, Maestroni GJ (2015) Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives. Front Cell Neurosci 9:302. doi:10.3389/fncel.2015.00302 CrossRefPubMedPubMedCentral

Dal Monte M, Fornaciari I, Nicchia GP, Svelto M, Casini G, Bagnoli P (2014) β3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling. Naunyn Schmiedebergs Arch Pharmaco 387:533–543. doi:10.1007/s00210-014-0969-1 CrossRef

Diaz ES, Karlan BY, Li AJ (2012) Impact of β blockers on epithelial ovarian cancer survival. Gynecol Oncol 127:375–378. doi:10.1016/j.ygyno.2012.07.102 CrossRefPubMed

Eng JW, Kokolus KM, Reed CB, Hylander BL, Ma WW, Repasky EA (2014) A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response. Cancer Immunol Immunother 63:1115–1128. doi:10.1007/s00262-014-1617-9 CrossRefPubMedPubMedCentral

Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ (2010) Ligand-directed signalling at β-adrenoceptors. Br J Pharmacol 159:1022–1038. doi:10.1111/j.1476-5381.2009.00602.x CrossRefPubMedPubMedCentral

Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed

Flierl MA et al (2007) Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 449:721–725. doi:10.1038/nature06185 CrossRefPubMed

Frishman WH, Saunders E (2011) β-Adrenergic blockers. J Clin Hypertens (Greenwich) 13:649–653. doi:10.1111/j.1751-7176.2011.00515.x CrossRef

Galandrin S, Bouvier M (2006) Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575–1584. doi:10.1124/mol.106.026716 CrossRefPubMed

Gargiulo L et al (2014) Differential β2-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines. Oncotarget 5:10058–10069. doi:10.18632/oncotarget.2460 CrossRefPubMedPubMedCentral

Goldstein DS (2003) Catecholamines and stress. Endocr Regul 37:69–80PubMed

Grazia Perrone M, Scilimati A (2010) β(3)-Adrenoceptor agonists and (antagonists as) inverse agonists history, perspective, constitutive activity, and stereospecific binding. Methods Enzymol 484:197–230. doi:10.1016/b978-0-12-381298-8.00011-3 CrossRefPubMed

Grytli HH, Fagerland MW, Fossa SD, Tasken KA (2014) Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 65:635–641. doi:10.1016/j.eururo.2013.01.007 CrossRefPubMed

Guimaraes S, Moura D (2001) Vascular adrenoceptors: an update. Pharmacol Rev 53:319–356. doi:10.3892/or_00001032 PubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013 CrossRefPubMed

Heitz F et al (2013) Impact of β blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO study group NCIC-CTG and EORTC-GCG. Gynecol Oncol 129:463–466. doi:10.1016/j.ygyno.2013.03.007 CrossRefPubMed

Hoffmann D, Rivenson A, Chung FL, Hecht SS (1991) Nicotine-derived N-nitrosamines (TSNA) and their relevance in tobacco carcinogenesis. Crit Rev Toxicol 21:305–311. doi:10.3109/10408449109017917 CrossRefPubMed

Inbar S, Neeman E, Avraham R, Benish M, Rosenne E, Ben-Eliyahu S (2011) Do stress responses promote leukemia progression? an animal study suggesting a role for epinephrine and prostaglandin-E(2) through reduced NK activity. PLoS One. doi:10.1371/journal.pone.0019246

Ji Y, Chen S, Xiao X, Zheng S, Li K (2012) β-blockers: a novel class of antitumor agents. Onco Targets Ther 5:391–401. doi:10.2147/ott.s38403 CrossRefPubMedPubMedCentral

Johannesdottir SA, Schmidt M, Phillips G, Glaser R, Yang EV, Blumenfeld M, Lemeshow S (2013a) Use of β-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer 13:85. doi:10.1186/1471-2407-13-85 CrossRefPubMedPubMedCentral

Johannesdottir SA, Schmidt M, Phillips G, Glaser R, Yang EV, Blumenfeld M, Lemeshow S (2013b) Use of ss-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer 13:85. doi:10.1186/1471-2407-13-85 CrossRefPubMedPubMedCentral

Lamkin DM et al (2016) β-Adrenergic-stimulated macrophages: comprehensive localization in the M1-M2 spectrum. Brain Behav Immun 57:338–346. doi:10.1016/j.bbi.2016.07.162 CrossRefPubMed

Le CP et al (2016) Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nature Commun 7:10634. doi:10.1038/ncomms10634 CrossRef

Lemeshow S et al (2011) β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 20:2273–2279. doi:10.1158/1055-9965.epi-11-0249 CrossRefPubMedPubMedCentral

Liao X, Che X, Zhao W, Zhang D, Bi T, Wang G (2010) The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncol Rep 24:1669–1676. doi:10.3892/or_00001032 PubMed

Lin X, Luo K, Lv Z, Huang J (2012) β-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. Hepatogastroenterology 59:584–588PubMed

Lin Q, Wang F, Yang R, Zheng X, Gao H, Zhang P (2013) Effect of chronic restraint stress on human colorectal carcinoma growth in mice. PLoS One 8:e61435. doi:10.1371/journal.pone.0061435 CrossRefPubMedPubMedCentral

Liu X, Wu WK, Yu L, Li ZJ, Sung JJ, Zhang ST, Cho CH (2008) Epidermal growth factor-induced esophageal cancer cell proliferation requires transactivation of β-adrenoceptors. J Pharmacol Exp Ther 326:69–75. doi:10.1124/jpet.107.134528 CrossRefPubMed

López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C (2004) Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 25:1454–1470. doi:10.1016/j.ehj.2004.06.003

Lutgendorf SK et al (2003) Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Cancer Res 9:4514–4521

Lutgendorf SK, Sood AK, Antoni MH (2010) Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol 28:4094–4099. doi:10.1200/jco.2009.26.9357 CrossRefPubMedPubMedCentral

Luthy IA, Bruzzone A, Pinero CP, Castillo LF, Chiesa IJ, Vazquez SM, Sarappa MG (2009) Adrenoceptors: non conventional target for breast cancer? Curr Med Chem 16:1850–1862. doi:10.2174/092986709788186048 CrossRefPubMed

Luttrell LM, Maudsley S, Bohn LM (2015) Fulfilling the promise of “biased” G protein-coupled receptor agonism. Mol Pharmacol 88:579–588. doi:10.1124/mol.115.099630 CrossRefPubMedPubMedCentral

Madden KS, Szpunar MJ, Brown EB (2011) β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines. Breast Cancer Res Treat 130:747–758. doi:10.1007/s10549-011-1348-y CrossRefPubMedPubMedCentral

Marino F, Cosentino M (2013) Adrenergic modulation of immune cells: an update. Amino Acids 45:55–71. doi:10.1007/s00726-011-1186-6 CrossRefPubMed

McCarty MF (2014) A role for cAMP-driven transactivation of EGFR in cancer aggressiveness—therapeutic implications. Med Hypotheses 83:142–147. doi:10.1016/j.mehy.2014.05.009 CrossRefPubMed

Monami M et al (2013) Further data on β-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Curr Med Res Opin 29:369–378. doi:10.1185/03007995.2013.772505 CrossRefPubMed

Moreno-Smith M (2010) Impact of stress on cancer metastasis. Future Oncol 6:1863–1881. doi:10.2217/fon.10.142 CrossRefPubMedPubMedCentral

Moretti S et al (2013) β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Invest 93:279–290. doi:10.1038/labinvest.2012.175 CrossRefPubMed

Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK (2013) β-blockers: a new role in cancer chemotherapy? Expert Opin Investig Drugs 22:1359–1363. doi:10.1517/13543784.2013.825250 CrossRefPubMedPubMedCentral

Nguyen KD (2011) Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 480:104–108. doi:10.1038/nature10653 CrossRefPubMedPubMedCentral

Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL (1996) Comparison of R-, S-, and RS-albuterol interaction with human β 1- and β 2-adrenergic receptors. Clin Rev Allergy Immunol 14:37–45. doi:10.1007/bf02772201 CrossRefPubMed

Perez D, Hébert T, Cotecchia S, Doze VA, Graham RM, Bylund DB, Altosaar K, Devost D, Gora S, Goupil E, Kan S, Machkalyan G, Michel MC, Sleno R, Summers R, Zylbergold P, Balaji P, Bond RA, Eikenburg DC, Hieble JP, Minneman KP, Sergio P, Hills R (2016) Adrenoceptors, introduction. Last modified on 10/08/2015. IUPHAR/BPS Guide Pharmacol. http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=4. Accessed 30 May 2016

Pérez Piñero C, Bruzzone A, Sarappa MG, Castillo LF, Lüthy IA (2012) Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol 166:721–736. doi:10.1111/j.1476-5381.2011.01791.x CrossRefPubMedPubMedCentral

Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Diz PG, Gandara Rey JM, Garcia-Garcia A (2010) β-adrenergic receptors in cancer: therapeutic implications. Oncol Res 19:45–54. doi:10.3727/096504010X12828372551867 CrossRefPubMed

Pimentel MA, Chai MG, Le CP, Cole SW, Sloan EK (2012) Sympathetic nervous system regulation of metastasis. In: Rahul Jandial and Kent Hunter (eds) Metastatic cancer: integrated organ system and biological approach, pp 1–11

Poirier L, Tobe SW (2014) Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol 30:S9–S15. doi:10.1016/j.cjca.2013.12.001 CrossRefPubMed

Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) β-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1:628–638. doi:10.18632/oncotarget.101009 CrossRefPubMedPubMedCentral

Rajagopal S, Rajagopal K, Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373–386. doi:10.1038/nrd3024 CrossRefPubMedPubMedCentral

Ramberg H et al (2008) Hormonal regulation of β2-adrenergic receptor level in prostate cancer. Prostate 68:1133–1142. doi:10.1002/pros.20778 CrossRefPubMed

Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, Bos JL (2003) Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the β 2-adrenergic receptor. J Cell Biol 160:487–493. doi:10.1083/jcb.200209105 CrossRefPubMedPubMedCentral

Scanzano A, Cosentino M (2015) Adrenergic regulation of innate immunity: a review. Front Pharmacol. doi:10.3389/fphar.2015.00171 PubMedPubMedCentral

Schuller HM (2010) β-adrenergic signaling, a novel target for cancer therapy? Oncotarget 1:466–469. doi:10.18632/oncotarget.101102 CrossRefPubMedPubMedCentral

Schuller HM (2013) Effects of tobacco constituents and psychological stress on the β-adrenergic regulation of non-small cell lung cancer and pancreatic cancer: implications for intervention. Cancer Biomark 13:133–144. doi:10.3233/cbm-130323 CrossRefPubMedPubMedCentral

Schuller HM, Cole B (1989) Regulation of cell proliferation by β-adrenergic receptors in a human lung adenocarcinoma cell line. Carcinogenesis 10:1753–1755. doi:10.1093/carcin/10.9.1753 CrossRefPubMed

Schuller HM, Witschi HP, Nylen E, Joshi PA, Correa E, Becker KL (1990) Pathobiology of lung tumors induced in hamsters by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the modulating effect of hyperoxia. Cancer Res 50:1960–1965PubMed

Schuller HM, Tithof PK, Williams M, Plummer H 3rd (1999) The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a β-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via β-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 59:4510–4515PubMed

Shan T, Cui X, Li W, Lin W, Li Y, Chen X, Wu T (2014) Novel regulatory program for norepinephrine-induced epithelial-mesenchymal transition in gastric adenocarcinoma cell lines. Cancer Sci 105:847–856. doi:10.1111/cas.12438 CrossRefPubMedPubMedCentral

Shang ZJ, Liu K, de Liang F (2009) Expression of β2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 38:371–376. doi:10.1111/j.1600-0714.2008.00691.x CrossRefPubMed

Shen SG, Zhang D, Hu HT, Li JH, Wang Z, Ma QY (2008) Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro. World J Gastroenterol 14:2358–2363. doi:10.3748/wjg.14.2358 CrossRefPubMedPubMedCentral

Shi M et al (2011) The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat 125:351–362. doi:10.1007/s10549-010-0822-2 CrossRefPubMed

Shi M et al (2013) Catecholamine-induced β2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J Immunol (Baltimore, MD: 1950) 190:5600–5608. doi:10.4049/jimmunol.1202364 CrossRef

Sloan EK et al (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70:7042–7052. doi:10.1158/0008-5472.can-10-0522 CrossRefPubMedPubMedCentral

Spiegel D (1994) Health caring. Psychosocial support for patients with cancer. Cancer 74:1453–1457CrossRefPubMed

Spiegel D, Giese-Davis J (2003) Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54:269–282CrossRefPubMed

Tang J, Li Z, Lu L, Cho CH (2013) β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol 23:533–542. doi:10.1016/j.semcancer.2013.08.009 CrossRefPubMed

Thaker PH et al (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939–944. doi:10.1038/nm1447 CrossRefPubMed

Thaker PH, Lutgendorf SK, Sood AK (2007) The neuroendocrine impact of chronic stress on cancer. Cell Cycle (Georgetown, TX) 6:430–433. doi:10.4161/cc.6.4.3829 CrossRef

Thiele M, Albillos A, Abazi R, Wiest R, Gluud LL, Krag A (2015) Non-selective β-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized. Liver Int 35:2009–2016. doi:10.1111/liv.12782 CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. doi:10.3322/caac.21262 CrossRefPubMed

Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011) Common cardiovascular medications in cancer therapeutics. Pharmacol Ther 130:177–190. doi:10.1016/j.pharmthera.2011.01.009 CrossRefPubMed

Wang L, Liu H, Chen X, Zhang M, Xie K, Ma Q (2012) Immune sculpting of norepinephrine on MHC-I, B7-1, IDO and B7-H1 expression and regulation of proliferation and invasion in pancreatic carcinoma cells. PLoS One 7:e45491. doi:10.1371/journal.pone.0045491 CrossRefPubMedPubMedCentral

Wang HM et al (2013) Improved survival outcomes with the incidental use of β-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24:1312–1319. doi:10.1093/annonc/mds616 CrossRefPubMedPubMedCentral

Watkins JL et al (2015) Clinical impact of selective and nonselective β-blockers on survival in patients with ovarian cancer. Cancer 121:3444–3451. doi:10.1002/cncr.29392 CrossRefPubMedPubMedCentral

Westfall TCWaDP (2011) Adrenergic agonists and antagonists. In: Brunton LL (ed) Goodman & Gilman’s the pharmacological basis of therapeutics, 12th edn. The McGraw-Hill

Wilson JM, Lorimer E, Tyburski MD, Williams CL (2015) β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells. Cancer Biol Ther 16:1364–1374. doi:10.1080/15384047.2015.1070988 CrossRefPubMedPubMedCentral

Wolter JK et al (2014) Anti-tumor activity of the β-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget 5:161–172. doi:10.18632/oncotarget.1083 PubMed

Wong HP et al (2011) Effects of adrenaline in human colon adenocarcinoma HT-29 cells. Life Sci 88:1108–1112. doi:10.1016/j.lfs.2011.04.007 CrossRefPubMed

Wu WK et al (2005) 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via β-adrenoceptors. Cancer Res 65:5272–5277. doi:10.1158/0008-5472.can-05-0205 CrossRefPubMed

Yang EV et al (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66:10357–10364. doi:10.1158/0008-5472.can-06-2496 CrossRefPubMed

Yang EV et al (2009) Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 23:267–275. doi:10.1016/j.bbi.2008.10.005 CrossRefPubMed

Zhang D, Ma QY, Hu HT, Zhang M (2010) β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol Ther 10:19–29. doi:10.4161/cbt.10.1.11944 CrossRefPubMed

Zhang P, He X, Tan J, Zhou X, Zou L (2011) β-Arrestin2 mediates β-2 adrenergic receptor signaling inducing prostate cancer cell progression. Oncol Rep 26:1471–1477. doi:10.3892/or.2011.1417 PubMed

Titel: β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives
verfasst von: Marisa Coelho
Cátia Soares-Silva
Daniela Brandão
Franca Marino
Marco Cosentino
Laura Ribeiro
Publikationsdatum: 05.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2278-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

The recommended treatment strategy for locally advanced gastric cancer in elderly patients aged 75 years and older: a Surveillance, Epidemiology, and End Results database analysis

Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma

Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study

Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer

Left-sided laterality of Merkel cell carcinoma in a German population: more than just sun exposure

Stromal factors involved in human prostate cancer development, progression and castration resistance

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie